trastuzumab botidexyl + toripalimab

F2F22A + DL001Z is a combination therapy consisting of **trastuzumab botidexyl** (DB-1303) and **toripalimab** (JS001). Trastuzumab botidexyl is a third-generation antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It utilizes a trastuzumab biosimilar backbone conjugated to a proprietary topoisomerase I inhibitor payload (P1003) via a stable, enzymatically cleavable peptide linker. This ADC is designed to deliver potent cytotoxic effects to HER2-expressing tumor cells, including those with low HER2 expression, while minimizing systemic toxicity. Toripalimab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore T-cell mediated anti-tumor activity. The combination is being investigated for its potential synergistic effects, where the ADC-induced immunogenic cell death may enhance the efficacy of PD-1 blockade in patients with advanced solid tumors.

Brand names

Tuoyi

Other names

F2F22A + DL001ZDB-1303 + toripalimabtrastuzumab botidexyl + toripalimab-tpzi